Pulmonx (NASDAQ:LUNG – Get Free Report) will post its quarterly earnings results after the market closes on Wednesday, July 31st. Analysts expect Pulmonx to post earnings of ($0.41) per share for the quarter. Pulmonx has set its FY 2024 guidance at EPS.Parties that are interested in registering for the company’s conference call can do so using this link.
Pulmonx (NASDAQ:LUNG – Get Free Report) last announced its quarterly earnings results on Wednesday, May 1st. The company reported ($0.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.43) by $0.07. Pulmonx had a negative net margin of 80.46% and a negative return on equity of 48.09%. The company had revenue of $18.85 million for the quarter, compared to analysts’ expectations of $17.54 million. During the same quarter in the previous year, the company earned ($0.42) earnings per share. On average, analysts expect Pulmonx to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
Pulmonx Stock Performance
Shares of LUNG opened at $7.04 on Tuesday. Pulmonx has a one year low of $5.67 and a one year high of $14.84. The company has a 50-day simple moving average of $7.05 and a two-hundred day simple moving average of $9.18. The company has a debt-to-equity ratio of 0.29, a current ratio of 6.95 and a quick ratio of 6.14. The firm has a market capitalization of $273.29 million, a PE ratio of -4.57 and a beta of 0.62.
Insider Transactions at Pulmonx
Wall Street Analyst Weigh In
Several equities research analysts recently weighed in on the company. Lake Street Capital began coverage on Pulmonx in a research note on Tuesday, June 4th. They issued a “buy” rating and a $12.00 price target on the stock. Canaccord Genuity Group reduced their target price on shares of Pulmonx from $16.00 to $15.00 and set a “buy” rating on the stock in a research report on Thursday, May 2nd. Finally, Piper Sandler reissued an “overweight” rating and set a $17.00 price target on shares of Pulmonx in a research report on Wednesday, April 3rd. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, Pulmonx presently has a consensus rating of “Moderate Buy” and a consensus price target of $15.71.
Get Our Latest Research Report on LUNG
About Pulmonx
Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.
Featured Articles
- Five stocks we like better than Pulmonx
- What is the NASDAQ Stock Exchange?
- Survey: Top 175 Fittest Retirement Locations in America
- How to Invest in Blue Chip Stocks
- Kimberly-Clark Stock Dips and a Buying Opportunity Emerges
- Stock Splits, Do They Really Impact Investors?
- Leading Gold Stock Shines With Q2 2024 Earnings Release
Receive News & Ratings for Pulmonx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmonx and related companies with MarketBeat.com's FREE daily email newsletter.